FDA reviewers advise limited use for Daiichi Sankyo's edoxaban
This article was originally published in Scrip
Executive Summary
While FDA drug reviewers recommended approval of Daiichi Sankyo's anticoagulant edoxaban at the 60mg once-daily dosage as a treatment to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF), they said the Factor Xa inhibitor should be limited for use in those with abnormal renal function.